Ocular Therapeutix Inc (NASDAQ: OCUL) is -14.05% lower on its value in year-to-date trading and has touched a low of $4.06 and a high of $11.77 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The OCUL stock was last observed hovering at around $6.54 in the last trading session, with the day’s gains setting it 0.8%.
Currently trading at $7.34, the stock is -3.72% and -1.92% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.86 million and changing 12.23% at the moment leaves the stock -13.10% off its SMA200. OCUL registered -15.54% loss for a year compared to 6-month loss of -15.63%. The firm has a 50-day simple moving average (SMA 50) of $7.484 and a 200-day simple moving average (SMA200) of $8.44655.
The stock witnessed a 12.92% gain in the last 1 month and extending the period to 3 months gives it a -12.10%, and is -4.30% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.76% over the week and 7.33% over the month.
Ocular Therapeutix Inc (OCUL) has around 274 employees, a market worth around $1.17B and $63.72M in sales. Profit margin for the company is -303.67%. Distance from 52-week low is 80.79% and -37.66% from its 52-week high. The company has generated returns on investments over the last 12 months (-49.72%).
with sales reaching $17.02M over the same period.The EPS is expected to grow by 0.74% this year, but quarterly earnings will post 11.43% year-over-year. Quarterly sales are estimated to grow 15.18% in year-over-year returns.
238.0 institutions hold shares in Ocular Therapeutix Inc (OCUL), with institutional investors hold 86.11% of the company’s shares. The shares outstanding are 157.75M, and float is at 133.91M with Short Float at 9.58%. Institutions hold 85.24% of the Float.
The top institutional shareholder in the company is SUMMER ROAD LLC with over 14.89 million shares valued at $101.82 million. The investor’s holdings represent 8.9767 of the OCUL Shares outstanding. As of 2024-06-30, the second largest holder is VR ADVISER, LLC with 12.76 million shares valued at $87.3 million to account for 7.6964 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 12.72 million shares representing 7.6716 and valued at over $87.01 million, while BLACKROCK INC. holds 6.9473 of the shares totaling 11.52 million with a market value of $78.8 million.
Ocular Therapeutix Inc (OCUL) Insider Activity
The most recent transaction is an insider sale by Dugel Pravin,. SEC filings show that Dugel Pravin sold 21,475 shares of the company’s common stock on Feb 24 ’25 at a price of $6.87 per share for a total of $0.15 million. Following the sale, the insider now owns 3.52 million shares.
Ocular Therapeutix Inc disclosed in a document filed with the SEC on Feb 24 ’25 that Heier Jeffrey S. (Chief Scientific Officer) sold a total of 3,061 shares of the company’s common stock. The trade occurred on Feb 24 ’25 and was made at $6.87 per share for $21029.0. Following the transaction, the insider now directly holds 0.27 million shares of the OCUL stock.
Still, SEC filings show that on Feb 24 ’25, Kaiser Peter (Chief Development Officer) disposed off 3,009 shares at an average price of $6.87 for $20672.0. The insider now directly holds 210,078 shares of Ocular Therapeutix Inc (OCUL).
